Table 2.

Search output of human studies providing information on basophils in patients with SLE.

Authorship	Articles Title	Findings
Charles et al. [41]	Basophils and the T-helper 2 environment can promote the development of lupus nephritis	In SLE, the presence of elevated serum IgE, self-reactive IgE, and activated CD62L+ and HLA-DR+ basophils are associated with active lupus nephritis and correlate with disease severity.
Dema et al. [44]	Immunoglobulin E plays an immunoregulatory role in lupus	The autoreactive IgE in SLE patients is associated with basophil activation and correlates with disease severity.
Liang et al. [45]	Basophil count, a marker for disease activity in systemic lupus erythematosus.	Different basophil counts in patients with active and nonactive disease, respectively.
Dijkstra. [46]	Human basophils modulate plasma cell differentiation and maturation	Basophils intensify proliferation and class switching in B-cell differentiation into plasma cells and production of immunoglobulins.
Pan et al. [42]	Basophil Activation-Dependent Autoantibody and Interleukin-17 Production Exacerbate Systemic Lupus Erythematosus	The presence of autoreactive IgE can mediate basophil activation in SLE. Basophils can amplify autoantibody production by B cells and promote Th17 differentiation.
Liang et al. [47]	Low level of circulating basophil counts in biopsy-proven active lupus nephritis	Prognostic value of basophil count in lupus nephritis.
Pellefigues et al. [48]	Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs	SLE patients have increased expression of PTGDR on basophils and elevated PGD2 metabolites.
Hasni et al. [49]	Safety and tolerability of omalizumab: A randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus.	Omalizumab may improve SLE activity by decreasing IFN-I production and impairing pDC and basophil activation.